Storm Therapeutics

Soft tissue sarcoma
#Investment #Sarcoma #Storm Therapeutics

STORM secures $56m financing for sarcoma treatment 

Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment.  The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study… Read More

#Business & Investment #News

#Cancer research #RNA #Storm Therapeutics

Biotech companies to develop epitranscriptomic cancer therapies 

Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications.  STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition.   Post-transcriptional modification of RNA, including N6-methyladenosine… Read More

#Business & Investment #Cancer Research #News

Cancer tumour
#Cancer therapeutics #Clinical trials #Immunology #Society of Immunotherapy for Cancer (SITC) #Storm Therapeutics

New clinical data on first-in-class METTL3 inhibitor 

Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024.    The Phase I clinical study… Read More

#News

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #RNA #RNA modifying enzymes #Storm Therapeutics

Could RNA modifying enzymes boost response rates? 

Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.   Turning points and catalysts… Read More

#Cancer Research #Exclusive Content #Opinion

Paris
#AI #Antibody drug conjugate (ADC) #DNA #ESMO #ESMO Targeted Anticancer Therapies Congress 2024 #RNA #Storm Therapeutics

Conversations from ESMO Targeted Anticancer Therapies Congress 2024 

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments… Read More

#Exclusive Content